We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M Turnover 28.57%
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+30.39%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$82.5M
AUM Growth
+$14.4M
Cap. Flow
-$5.05M
Cap. Flow %
-6.12%
Top 10 Hldgs %
85.52%
Holding
33
New
3
Increased
2
Reduced
3
Closed
7
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.4 years
Top 10 Avg Time Held Equity only
1.4 years
Top 20 Avg Time Held Equity only
1.4 years

Top Buys

Rank Stock Value
1
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
+$1.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$2.68M
2
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.43M
3
AMRI
Albany Molecular Research Inc
AMRI
+$1.46M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$269K

Sector Composition

Rank Sector Weight
1 Healthcare 64.22%
2 Miscellaneous 35.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ANIP icon
1
ANI Pharmaceuticals
ANIP
$1.65B
$19.3M 23.35%
345,000
-50,000
-13% -$2.43M
2015 Q2
4 quarters
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$805B
$15.7M 19.05%
75,000
+50,000
+200% +$10.4M
2016 Q1
1 quarter
ASRT icon
3
DELISTED
Assertio
ASRT
$6.87M 8.32%
5,833
– –
2015 Q4
2 quarters
PFE icon
4
Pfizer
PFE
$168B
$6.16M 7.47%
184,450
– –
2014 Q1
9 quarters
DGX icon
5
Quest Diagnostics
DGX
$25.8B
$5.39M 6.53%
66,208
– –
2013 Q2
12 quarters
AORT icon
6
Artivion
AORT
$1.06B
$4.72M 5.73%
400,000
– –
2014 Q3
7 quarters
AMRI
7
DELISTED
Albany Molecular Research Inc
AMRI
$4.06M 4.93%
302,400
-100,000
-25% -$1.46M
2014 Q1
9 quarters
QLTI icon
8
DELISTED
QLT Inc
QLTI
$3.06M 3.71%
2,157,200
– –
2014 Q4
6 quarters
ANIP icon
9
PUT
ANI Pharmaceuticals
ANIP
$1.65B
$2.79M 3.38%
+50,000
New +$2.43M
2016 Q2
0 quarters
AMAG
10
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$2.51M 3.05%
+105,000
New +$2.41M
2016 Q2
0 quarters
ASRT icon
11
CALL
DELISTED
Assertio
ASRT
$1.96M 2.38%
1,667
– –
2016 Q1
1 quarter
ARLZ
12
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$1.9M 2.3%
575,000
+475,000
+475% +$1.79M
2016 Q1
1 quarter
TWM icon
13
CALL
ProShares UltraShort Russell2000
TWM
$70.5M
$1.74M 2.11%
2,500
– –
2015 Q2
4 quarters
CYTK icon
14
Cytokinetics
CYTK
$8.64B
$949K 1.15%
100,000
– –
2014 Q4
6 quarters
VIXY icon
15
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$246M
$916K 1.11%
+63
New +$1.04M
2016 Q2
0 quarters
TWM icon
16
ProShares UltraShort Russell2000
TWM
$70.5M
$871K 1.06%
1,250
– –
2014 Q1
9 quarters
SGNT
17
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$749K 0.91%
50,000
– –
2016 Q1
1 quarter
AMRI
18
CALL
DELISTED
Albany Molecular Research Inc
AMRI
$672K 0.81%
50,000
– –
2016 Q1
1 quarter
AORT icon
19
CALL
Artivion
AORT
$1.06B
$591K 0.72%
50,000
– –
2016 Q1
1 quarter
SGNT
20
CALL
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$524K 0.64%
35,000
– –
2016 Q1
1 quarter
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
$256K 0.31%
31,850
– –
2015 Q1
5 quarters
ARLZ
22
CALL
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$248K 0.3%
75,000
-100,000
-57% -$377K
2016 Q1
1 quarter
SEEL icon
23
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
2016 Q1
1 quarter
FCSC
24
DELISTED
Fibrocell Science Inc.
FCSC
$170K 0.21%
9,851
– –
2014 Q1
9 quarters
QLTI icon
25
CALL
DELISTED
QLT Inc
QLTI
$142K 0.17%
100,000
– –
2016 Q1
1 quarter
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Healthcare Value Capital held 33 positions worth $82.5M, up 21% from $68.1M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Healthcare Value Capital withdrew a net $5.05M in Q2 2016, closing 7 positions and reducing 3 holdings. Its most notable exit was Allergan plc, an estimated $2.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 70% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital added an estimated $1.79M to Aralez Pharmaceuticals Inc..

  • Healthcare Value Capital added most to Aralez Pharmaceuticals Inc. in Q2 2016, an estimated $1.79M increase.
  • Healthcare Value Capital's biggest Q2 2016 reduction was ANI Pharmaceuticals, cutting an estimated $2.43M.
  • Healthcare Value Capital fully exited Allergan plc in Q2 2016, selling an estimated $2.68M.
  • Healthcare Value Capital's ten largest holdings make up 86% of its $82.5M portfolio in Q2 2016.
  • Healthcare Value Capital opened 3 new positions and closed 7 in Q2 2016.
  • Healthcare Value Capital's portfolio value rose 21% quarter-over-quarter to $82.5M.

Based on Healthcare Value Capital's 13F filing for Q2 2016, filed 15 Aug 2016.